Please assess the completion status of the following clinical trial:

Trial Title: Dose-Dense Induction/Neoadjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with documented stage III NSCLC (IIIA or IIIB, without malignant pleural/pericardial effusion) are eligible for enrollment if they are considered appropriate for treatment with chemotherapy, radiation, or surgery;~* IIIA: T1-3 N2 M0, T3 N1 M0~* IIIB: T4 N0-2 M0, T 1-4 N3 M0~* Measurable or evaluable disease~* Previously untreated with chemotherapy or radiotherapy for lung cancer;~* No brain metastases;~* No prior XRT~* Performance status 0-2~* ≥18 years of age~* Informed Consent~* Absolute neutrophil count (ANC) ≥ 1.5 x 109/L~* Platelets ≥ 100 x 109/L~* Bilirubin ≤ 1.5 x upper limit of normal for the institution (ULN)~* SGOT and SGPT ≤ 2.5 x ULN for the institution~* Creatinine ≤ 1.6 mg/dL~* Hemoglobin ≥ 8.0 g/dL~* Peripheral neuropathy ≤ grade 1~Exclusion Criteria:~* Known sensitivity to E. coli derived products (e.g. Filgrastim, HUMULIN® insulin, L-asparaginase, HUMATROPE® Growth Hormone, INTRON® A);~* Use of IV systemic antibiotics within 72 hours prior to chemotherapy;~* Known HIV infection~* Lithium or cytokines within 2 weeks prior of entry~* Additional concurrent investigational drugs~* History of myelodysplastic syndrome~* Pregnant, nursing or having unprotected sex~* Not available for follow-up assessment~* Unable to comply with protocol procedures~* Illnesses that may compromise ability to give informed consent.~* Patients with a history of severe hypersensitivity reaction to Taxotere® or other drugs formulated with polysorbate 80.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Induction Chemotherapy (Type: EXPERIMENTAL): Cisplatin 75mg/m2 IV days 1, 15, 29; Docetaxel 75mg/m2 IV days 1, 15, 29; and Pegfilgrastim 6mg SC day 2, 16, 30

Based on this trial design, predict the completion outcome and termination type (if applicable).